title: Anti-tumour necrosis factor agents and lipid profile: a class effect?
authors.forename: S P
authors.initials: SP
authors.lastname: Garcês
authors.forename: M J
authors.initials: MJ
authors.lastname: Parreira Santos
authors.forename: F M R
authors.initials: FM
authors.lastname: Vinagre
authors.forename: R M
authors.initials: RM
authors.lastname: Roque
authors.forename: J A C
authors.initials: JA
authors.lastname: da Silva
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000378:metabolism; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D050356:Lipid Metabolism; D008233:Lymphotoxin-alpha / Q000037:antagonists & inhibitors*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D008233:Lymphotoxin-alpha; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept